descr

PaxVax ready to strike M&A deals that prove its sales model, CEO says

Thursday, January 15, 2015

PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says.

The California company has another specialty travel vaccine deal coming that it's currently negotiating, the helmsman told FierceVaccines in an interview at this week's JP Morgan Healthcare Conference. It expects to announce that pact--along with one for a travel med--in the first half of this year.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

to Better the World

Innovative. Beneficial. Simple.

Our mission is to develop and commercialize innovative vaccines against infectious diseases in a socially responsible manner.

 

VaccineNation Names PaxVax CTO Dr. Thomas Monath #2 Most Influential Person in Vaccines

 

Read more

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS